FXYD3 and neoplasm: FXYD3 knockdown resulted in a markedly reduced tumor burden, as evidenced by fewer tumors, smaller tumor volumes, and a decreased liver weight‐to‐body weight (LW/BW) ratio, compared to controls (Figure 4F,G).